A New Window Into the Immune System: ISB Researchers Develop Powerful Platform to Decode CD4+ T Cells
Researchers at the Institute for Systems Biology have developed a powerful new platform that can identify and deeply profile antigen-specific CD4+ T cells at unprecedented scale and resolution. Published in Nature Communications, the work could help accelerate vaccine design, improve immune monitoring, and advance next-generation cancer immunotherapies.
For decades, scientists have known that CD4+ T cells play a central role in orchestrating the immune system’s response to infection and cancer. But studying those cells in detail — especially at scale — has remained technically difficult.
Now, researchers at the Institute for Systems Biology (ISB) have developed a new platform that allows scientists to identify, track, and deeply characterize antigen-specific CD4+ T cells across many patients and time points simultaneously.
Published in Nature Communications, the study introduces a high-throughput approach capable of connecting multiple layers of immune information at once: what individual CD4+ T cells recognize, how they behave, how they evolve over time, and which patients they come from — all at single-cell resolution.
The work could help researchers better understand immune responses to infectious diseases, improve vaccine design, and accelerate the development of new cancer immunotherapies.
“This is really about giving us a much more complete picture of adaptive immunity,” said ISB President and Professor Dr. Jim Heath, senior author of the study. “CD4 T cells are enormously important because they help coordinate and mature immune responses. But they’ve been much harder to study comprehensively than CD8 T cells. This platform changes that.”
Building a ‘Search Engine’ for CD4+ T Cells
The new platform, called APMAT-CD4, builds on earlier work from the Heath Lab focused on CD8+ T cells. In the new study, the team adapted the technology to address the greater complexity of CD4+ T cells and the class II MHC molecules they recognize.
Unlike CD8+ T cells — which primarily destroy infected or cancerous cells — CD4+ T cells act more like coordinators of the immune system. They help activate B cells, recruit other immune cells, and shape long-term immune memory.
But the biology is more difficult to analyze.
“CD4 T cells recognize antigens presented through class II MHC molecules, and those interactions are much more flexible and variable,” said Dr. Rongyu Zhang, the study’s lead author and a postdoctoral fellow in the Heath Lab. “That flexibility is biologically important, but it also makes the system much harder to study and predict.”
To overcome that challenge, the researchers engineered what are known as single-chain trimers — synthetic molecules that combine the antigen and MHC molecule into a single construct. That allowed the team to rapidly generate large libraries of antigens and screen thousands of antigen-specific CD4+ T cells in parallel.
The approach enabled researchers to perform what Heath describes as a kind of “massively parallel search engine” for the immune system.
“We can now screen huge numbers of antigens, patients, and time points in a single experiment,” Heath said. “And importantly, we’re not just identifying the cells. We’re simultaneously learning what they recognize, what state they’re in, how they’re evolving, and how they differ between patients.”
Mapping Immune Responses to COVID-19
To demonstrate the platform’s capabilities, the team applied APMAT-CD4 to samples from 22 individuals infected with SARS-CoV-2, the virus that causes COVID-19.
The researchers screened the virus’s receptor-binding domain — a key portion of the spike protein targeted by vaccines and antibodies — and identified more than 2,000 antigen-specific CD4+ T cells across patients and time points.
The resulting dataset allowed the team to observe how immune responses evolved over time, from acute infection through recovery and, in some cases, years later.
One of the study’s major findings was that they could sort rank viral antigens by the strength of the immune responses that they triggered – from strong to weak.
“We found that some antigens consistently generated much more immunogenic CD4 T-cell responses than others,” Zhang said. “And interestingly, those highly immunogenic antigens tended to behave similarly across many different patients.”
The team also found that stronger CD4+ T-cell responses correlated with higher antibody levels later in recovery, suggesting that the platform could help identify viral targets most important for protective immunity.
That insight could eventually help guide the design of more precise vaccines.
“If you can identify which antigens produce the strongest and most durable helper T-cell responses, that gives you a rational framework for vaccine design,” Heath said. “That’s especially important for future emerging infectious diseases.”
Insights into Long COVID
The study also included a detailed longitudinal analysis of a patient experiencing long COVID symptoms.
Over several years, the researchers observed persistent CD4+ T-cell activity against SARS-CoV-2 antigens, suggesting the possibility of ongoing viral or antigen persistence in some patients.
“We saw continued generation of antigen-specific CD4 T-cell responses long after the initial infection,” Zhang said. “That’s consistent with the idea that some patients may continue harboring viral reservoirs or persistent antigen exposure.”
While the researchers caution that larger studies are needed, the findings highlight the potential for the platform to help identify biomarkers and mechanisms underlying long COVID.
Toward Next-Generation Cancer Immunotherapies
Beyond infectious disease, the team also applied the technology to HPV-associated precancerous lesions.
Using samples from patients with HPV-16 infections, the researchers identified CD4+ T-cell receptors capable of recognizing HPV-related cancer targets. Several demonstrated strong therapeutic potential in preclinical testing.
The work points toward a future in which CD4+ T cells could play a larger role in engineered T-cell therapies for cancer.
“Most current T-cell therapies focus heavily on CD8 T cells,” Heath said. “But CD4 T cells help organize and sustain broader anti-tumor immune responses. This opens the door to building more balanced and potentially more effective immunotherapies.”
For Zhang, the broader significance of the work lies in its versatility.
“This is fundamentally a platform technology,” Zhang said. “It can be applied across infectious disease, cancer, autoimmunity, vaccine research, and many other areas where understanding antigen-specific immune responses matters.”
